Results of a Phase III clinical study using botulinum toxin type A to treat primary axillary hyperhidrosis, or excessive underarm sweating, show that botulinum toxin type A is safe and effective for ...
Feb. 10, 2004 (Washington) -- Intradermal botulinum toxin type A (BTX-A) appears to be safe and effective for repeated treatment of hyperhidrosis, according to new research. Dee Anna Glaser, MD, a ...
Introduction: Axillary hyperhidrosis can be a source of social isolation and embarrassment. The available treatments are either ineffective or have intolerable side effects. The search for a simple, ...
(HealthDay)—For patients with hyperhidrosis, botulinum toxin treatment is associated with significant improvements in mental and physical health, according to a study published online Feb. 15 in the ...
(HealthDay News) — For patients with hyperhidrosis, botulinum toxin treatment is associated with significant improvements in mental and physical health, according to a study published online Feb. 15 ...
NEW YORK, March 18, 2023 /PRNewswire/ -- Aquavit Holdings has submitted to FDA an IND for its DTX-024, for the treatment of palmar hyperhidrosis using its patented microchannel technology™. DTX-024 is ...
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical Trial ...
ST. LOUIS - Results of a Phase III clinical study using botulinum toxin type A to treat primary axillary hyperhidrosis, or excessive underarm sweating, show that botulinum toxin type A is safe and ...
- This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis - - The Company recently entered into a Clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results